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Abstract
We studied the effects on pulmonary hemodynamics of U-
46619, a thromboxane A2 (TXA2) agonist, before and after
administration of a novel TXA2 receptor antagonist and syn-
thase inhibitor (BM-573). Six anesthetized pigs (Ago group)
received 6 consecutive injections of U-46619 at 30-min inter-
val and were compared with six anesthetized pigs (Anta
group) which received an increasing dosage regimen of 
BM-573 10min before each U-46619 injection. Consecutive
changes in pulmonary hemodynamics, including characteris-
tic resistance, vascular compliance, and peripheral vascular
resistance, were continuously assessed during the experi-
mental protocol using a four-element Windkessel model. At
2mg/kg, BM-573 completely blocked pulmonary hyperten-
sive effects of U-46619 but pulmonary vascular compliance
still decreased. This residual effect can probably be explained
by a persistent increase in the tonus of the pulmonary vascu-
lar wall smooth muscles sufficient to decrease vascular com-
pliance but not vessel lumen diameter. Such molecule could
be a promising therapeutic approach in TXA2 mediated pul-
monary hypertension as it is the case in pulmonary embolism,
hyperacute lung rejection and endotoxinic shock.
Keywords: Models, pulmonary circulation, swine, throm-
boxane, vascular compliance, vascular resistance.
Introduction
Thromboxane A2 (TXA2) is a potent vasoconstrictor and
aggregating agent produced by platelets, leukocytes and
endothelial cells (Hamberg et al., 1975; Oates et al., 1988).
It is a very labile molecule, with a half-life of approximately
30secs in aqueous media, and it is hydrolyzed to form a
stable but inactive metabolite, thromboxane B2 (TXB2)
(Oates et al., 1988).
TXA2 has been implicated as a pro-inflammatory media-
tor during the pulmonary hypertensive phase of Gram-
negative sepsis (Wise et al., 1981) and of hyperacute lung
rejection (Collins et al., 2001; Ogletree & Brigham, 1982).
It is also an agent responsible for pulmonary vasocon-
striction in pulmonary embolism (Smulders, 2000) and a
pathophysiological mediator in thrombosis, vasospasm,
arrhythmias and progression of ischemic damage after coro-
nary occlusion (Oates et al., 1988).
In such pathological conditions, potential benefits of
blocking TXA2 effects were investigated by testing inhibitors
of TXA2 biosynthesis. These inhibitors were rapidly found
ineffective because of an incomplete blockage of thrombox-
ane synthase at the dosage used and because TXA2 synthase
inhibition induces the accumulation of a TXA2 precursor
called endoperoxide H2 (PGH2) which is chemically more
stable and exerts similar biological effects by acting at
common receptors. However, specific inhibitors of TXA2
synthase are also responsible for increasing generation of
prostanoids such as prostaglandin I2, which can be beneficial
by attenuating platelet activation and decreasing vascular
resistance. Therefore, efforts to modulate the actions of 
TXA2 focused on agents able to block biosynthesis of TXA2
and to antagonize both PGH2 and TXA2 at their common
receptor (Oates et al., 1988; Vandeplassche et al., 1991; 
Vandeplassche et al., 1993).
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BM-573 is a molecule derived from the pyridine sulfony-
lurea torasemide, a loop diuretic. It is obtained by the
replacement of the pyridine ring of torasemide with a
nitrobenzene and the presence of a tert-butyl group on the
distal nitrogen of the sulfonylurea function which improved
the TXA2 antagonism and revealed TXA2 synthase inhibitory
potency (Fig. 1) (Rolin et al., 2001). This novel TXA2 recep-
tor antagonist and synthase inhibitor has a powerful
antiplatelet potency and was shown to relax the rat aorta
artery precontracted with U-46619 (Rolin et al., 2001).
As current evidence suggests that TXA2 plays a role in
pathophysiologic processes in the lung, we tested whether
this new dual TXA2 synthase inhibitor and TXA2 receptor
antagonist was able to antagonise pulmonary hemodynamic
effects of U-46619, a stable TXA2 agonist. Therefore, we
studied the effects of U-46619 on pulmonary hemodynam-
ics after administration of BM-573 using a four-element
windkessel model (Grant & Paradowski, 1987; Lambermont
et al., 1999).
Materials and methods
All experimental procedures and protocols used in this 
investigation were reviewed and approved by the Ethics
Committee of the Medical Faculty of the University of 
Liege. They were performed in accordance with the 
European Community Guidelines for the use of experimen-
tal animals.
Experiments were performed on 12 healthy pure pietran
pigs of either sex weighing from 20 to 30kg. The animals
were premedicated with intramuscular administration of ket-
amine (20mg/kg) and diazepam (1mg/kg). Anesthesia was
then induced and maintained by a continuous infusion of
sufentanil (0.5mg/kg/h) and pentobarbital (5mg/kg/h). Spon-
taneous movements were prevented by pancuronium bromide
(0.2mg/kg/h). After endotracheal intubation through a cervi-
cal tracheostomy, the pigs were connected to a volume cycled
ventilator (Evita 2, Dräger, Lübeck, Germany) set to deliver
a tidal volume of 15mL/kg at a respiratory rate of 20
breaths/min. End-tidal CO2 measurements (Capnomac,
Datex, Helsinki, Finland) were used to monitor the adequacy
of ventilation. Respiratory settings were adjusted to maintain
end-tidal CO2 between 30 and 35mmHg. Arterial oxygen sat-
uration was monitored closely and maintained at >95% by
adjusting the FiO2 as necessary.
The pulmonary trunk was exposed by means of medial
sternotomy. A micromanometer-tipped catheter (Sentron
pressure-measuring catheter, Cordis, Miami, FL) was
inserted into the main pulmonary artery through a stab
wound in the right ventricular outflow tract. A 14mm diam-
eter perivascular flow probe (Transonic Systems, Ithaca, NY)
was closely adjusted around the main pulmonary artery 2cm
downstream of the pulmonary valve. The micromanometer-
tipped catheter was manipulated so that the pressure sensor
was finally positioned very close to the flow probe.
Left atrial pressure was measured with a micromanometer-
tipped catheter inserted into the cavity through the left atrial
appendage. Finally, systemic blood pressure was monitored
with a micromanometer-tipped catheter inserted into the
descending thoracic aorta through the left femoral artery.
Chemicals
U-46619 (Cayman Chemical, Ann Arbor, MI) supplied in
ethanolic solution was diluted in NaCl 0.9% solution to a
final concentration of 10 mg/ml. BM-573 was obtained from
the laboratory of Medicinal Chemistry of the University of
Liège. It was dissolved in propyleneglycol and water to
achieve a drug solution of 20mg/ml.
Experimental protocol
After a 30min stabilization period, animals were randomisely
divided in two groups. In the first group (n = 6) (Ago group)
the animals received six consecutive injections of the 
same dose of U-46619 (1.25 mg/kg) at a 30min interval.
Hemodynamic data were recorded before each injection 
of U-46619 (TO) and 2 (T2), and 15 (T15) mins after 
each injection of U-46619. Hemodynamic data included 
pulmonary artery pressure wave (PAP), pulmonary blood
flow wave (CO), left atrial pressure, systemic arterial 
pressure (BP), and heart rate (HR).
In the second group (n = 6) (Anta group), an increasing
dosage regimen of BM-573 was administrated intavenously
10min before each U-46619 injection, with the exception 
of the first U-46619 injection which was not preceded by 
an antagonist injection. The animals received 0.125mg/kg 
of BM-573 before the second, 0.250mg/kg before the 
third, 0.500mg/kg before the fourth, 1mg/kg before the fifth
and 2mg/kg before the sixth agonist injection. In the 
Anta group, hemodynamic data were recorded before each
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Fig. 1. Chemical structure of the TXA2 receptor antagonist and
synthase inhibitor BM-573.
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antagonist injection (Anta 0, Anta 0.125, Anta 0.25, Anta 0.5,
Anta 1, Anta2), 10min later (i.e., just before agonist injec-
tion) (T0), and 2 (T2) and 15 (T15) min after each injection
of U-46619.
In both groups, each sequence of agonist injection and the
corresponding recordings of data (T0, T2, T15) were called
Run 0, Run 0.125, Run 0.250, Run 0.500, Run 1, Run 2,
respectively, according to the dose of antagonist injected in
the Anta group.
Data collection
All analog signals were continuously converted to digital
form with an appropriate system (Codas, DataQ instruments
inc., Akron, OH). The pressure and flow waves were sampled
at 200Hz and stored on files. Cardiac cycles were delimited
by R wave detection provided by a permanent recording of a
one lead electrocardiogram. Ten consecutive cycles were
recorded during apneic phase and numeri-cally averaged to
obtain representative diagrams of pressure and flow waves
corresponding to specific experimental conditions.
Data analysis
A lumped parameter model, namely the four-element wind-
kessel model (WK4) (Fig. 2), was used to analyze the flow
conditions in the pulmonary circulation throughout the
experimental protocol. The resistor R2 represents the resis-
tive properties of the pulmonary vasculature which are con-
sidered to reside primarily in the arteriolar system. The
capacitor C, placed in parallel with R2 , represents the com-
pliant properties of the pulmonary arterial tree (Grant &
Paradowski, 1987). The resistor R1 is used to reflect charac-
teristic resistance which level depends prominently on the
resistance and compliance of the main pulmonary artery.
Finally, an inductance L is added to allow positive phases
angles between flow and pressure waves and accounts for the
inertial properties of the blood and for the viscous resistive
properties of the vessels wall (Grant & Paradowski, 1987).
The four elements of the model were simultaneously identi-
fied by using an original analytic procedure previously
described (Lambermont et al., 1998).
Statistical analysis
Data are presented as mean ± standard error of the mean
(SEM).
A factorial design with 3 fixed effects (time, run, pig) 
of order 2 was used to determine the effects of time and run
on the different parameters values (Statistica ’99 edition,
Statsoft Inc, Tulsa, OK, USA).
For evaluation of differences between groups, Student’s 
t-test was applied.
P < 0.05 was considered statistically significant.
Results
Conventional hemodynamic variables
Time course of conventional hemodynamic variables for both
groups is presented in Figure 3.
Ago group
In Ago group, PAP increased from a mean value of 22.8 ±
0.8mmHg at T0 to 47.2 ± 1.7mmHg (p < 0.05) 2min after
injection of U-46619 (T2) and returned to baseline values (25
± 0.8mmHg) 15min later (T15). A progressive increase in
PAP values at T0, T2 and T15 was observed between Runs
(Fig. 3).
CO decreased from 91.3 ± 2.9ml/s (T0) to 63 ± 4.2ml/s
(T2) (p < 0.05) after administration of U-46619. This
decrease in CO following administration of U-46619 at T2
worsened over time. It decreased from 110 ± 2.8 to 96 ±
3.2ml/s (p < 0.05) during the first Run (Run 0) and from 81
± 3.1 to 47 ± 7.4ml/s (p < 0.05) during the last Run (Run 2),
while HR increased from 123 ± 3.4beats/min (T0) to 137 ±
4.7beats/min (T2) (p < 0.05) and returned to baseline values
at T15 (122 ± 3.5beats/min).
BP slightly increased following the injection of U-46619
in the first Runs (Run 0, Run 0.125, Run 0.250, Run 0.500,
respectively) while in both Run 1 and Run 2 BP decreased
slightly after U-46619 injection.
Anta group
There is no difference between Ago and Anta groups during
Run 0. From Run 0.125, PAP showed an increase which was
less important in Anta group than in Ago group (p < 0.05)
while in Run 2, PAP remained constant after administration
of U-46619. HR and CO were not influenced by the 
injection of U-46619 which followed a 0.125mg/kg BM-573
injection (Run 0.125).
Pulmonary hemodynamics
Time course of calculated pulmonary vascular parameters as
provided by the WK4 model is presented in Figure 4.
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Fig. 2. Electrical representation of the four-element windkessel
model. It is composed of a characteristic resistance (R1), a periph-
eral resistance (R2), a compliance (C), and an inductance (L).
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Fig. 3. Time course of conventional hemodynamic variables in the Ago group (Closed circle) and the Anta group (Open square) before U-
46619 injection (T0), 2 min after U-46619 injection (T2) and 15 min after U-46619 injection (T15) in both Ago and Anta group and, in Anta
group, before BM-573 injection (Anta 0.125, Anta 0.500, Anta 1, Anta 2, according to the dose of BM-573 injected (mg/kg)).
* p < 0.05 Ago group vs Anta group.
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Ago group
R1 and R2 followed exactly the same pattern (Fig. 4). They
increased at T2 and returned to baseline values at T15. Values
at T0 were remarkably stable between Runs. C decreased
largely at T2 during each Run and returned almost at the pre-
vious value of T0 with a slight decrease over time of T0 values.
Anta group
There was no difference between Ago and Anta groups
during Run 0. From Run 0.125 and Run 0.250, R1 and R2,
respectively, did not increase after administration of U-46619
and remained remarkably stable over time. However, U-
46619 decreased C values at T2 in all Runs in both groups
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Fig. 4. Time course of calculated pulmonary vascular parameters as obtained by the four-element windkessel model of the pulmonary cir-
culation in the Ago group (Closed circle) and the Anta group (Open square) before U-46619 injection (T0), 2 min after U-46619 injection
(T2) and 15 min after U-46619 injection (T15) in both Ago and Anta group and, in Anta group, before BM-573 injection (Anta 0.125, Anta
0.500, Anta 1, Anta 2, according to the dose of BM-573 injected (mg/kg)). R1, characteristic vascular resistance; R2, peripheral vascular resis-
tance; C, vascular compliance.
* p < 0.05 Ago group vs Anta group.
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but C was significantly higher in Anta group than in Ago
group at T2 from Run 0.5 (p < 0.05).
Discussion
Pulmonary vasonctriction caused by the release of predomi-
nantly vasoconstrictive mediators, is an important contribu-
tor to the increase in pulmonary vascular resistance in
patients with acute pulmonary embolism, hyperacute lung
rejection or during the early phase of septic shock (Collins
et al., 2001; Lambermont et al., 1999; Smulders, 2000). In
septic shock, right heart failure can lead to death (Kimchi et
al., 1984) and, in pulmonary embolism, most patients who
succumb do so within minutes to few hours after onset of
symptoms. Therefore drugs that antagonise vasoconstrictive
mediators could be effective overall if given in the initial
phase of hemodynamic instability.
When pulmonary cyclooxygenase activity is inhibited, the
importance of endothelial prostacyclin synthesis to preser-
vation of transpulmonary blood flow is apparent. In contrast
to selective antithromboxane strategy which results in pre-
served transpulmonary blood flow, inhibition of both prosta-
cyclin and thromboxane in dogs with oleic acid lung injury
is associated with significantly elevated pulmonary vascular
resistance (Leeman et al., 1988). Wether TXA2 directly
affects pulmonary microvascular integrity is controversial.
Nevertheless, TXA2 has postvenular vasoconstrictive effects
(Schuster et al., 2001) and therefore increases microvascular
fluid transudation by causing increased hydrostatic pressure
in pulmonary capillary beds (Collins et al., 2001).
TXA2 has also proinflammatory effects and reduced TXA2
effects generally correlates with a blunted inflammatory
response (Collins et al., 2001).
In previous in vitro and in vivo studies, it has been demon-
strated that BM-573 was a potent dual compound able to
reduce TXA2 production by thromboxane synthase inhibition
and to prevent the action of TXA2 (or PGH2) by blocking the
TXA2 receptors (Rolin et al., 2001). The results of the present
study evidence that the pulmonary vascular responses to the
TXA2 stable agonist, U-46619, were markedly reduced by a
2mg/kg injection of BM-573.
As expected, in Ago group, U-46619 increased pulmonary
artery pressure in response to increases in pulmonary 
vascular resistances (Kaye et al., 1995; Sjoberg & Steen,
1989). In Runs 1 and 2, PAP increased to a level high 
enough to provoke a fall in CO associated to a paradoxal
decrease in BP.
Our data showed that BM-573 completely blocked pul-
monary hypertensive effects of U-46619. However, at the
regimen of 2mg/kg and, in spite of the lack of effects on
resistance, pulmonary vascular compliance still decreased
after administration of the TXA2 agonist. This residual 
effect can probably be explained by a persistent increase in
the tonus of the pulmonary vascular wall smooth muscles
sufficient to decrease vascular compliance but not vessel
lumen diameter. The inhibition of TXA2 synthase by BM-573
was not investigated in the present study but, as previously
demonstrated, BM-573 completely reduced the platelet 
production of TXB2 induced by arachidonic acid (Rolin et
al., 2001).
In essence, our data suggest that the present antagonist
could be a promising therapeutic approach in the field of
bocking TXA2 in pulmonary hypertension secondary to 
pulmonary embolism, hyperacute lung rejection or septic
shock not only because BM-573 administration blocks TXA2
induced pulmonary vasoconstriction but also because it can
prevent platelet aggregation and decrease inflammatory
response.
Acknowledgements
This work was supported by grants from the Belgian 
Fonds National de la Recherche Scientifique (n° 3.4505.01)
and by the Communauté Française de Belgique (ARC n°
99/04-249).
References
Collins BJ, Blum MG, Parker RE, Chang AC, Blair KS, Zorn
GL, III, Christman BW, Pierson RN, III (2001): Throm-
boxane mediates pulmonary hypertension and lung inflam-
mation during hyperacute lung rejection. J Appl Physiol 90:
2257–2268.
Grant BJB, Paradowski LJ (1987): Characterization of pul-
monary arterial input impedance with lumped parameters
models. Am J Physiol 252: H585–H593.
Hamberg M, Svensson J, Samuelsson B (1975): Thromboxanes:
a new group of biologically active compounds derived from
prostaglandin endoperoxides. Proc Natl Acad Sci U S A 72:
2994–2998.
Kaye AD, Nossaman BD, Ibrahim IN, DeWitt BJ, Feng CJ, 
Kadowitz PJ (1995): Analysis of thromboxane receptor-
mediated responses in the feline pulmonary vascular bed.
Crit Care Med 23: 164–170.
Kimchi A, Ellrodt AG, Berman DS, Riedinger MS, Swan HJ,
Murata GH (1984): Right ventricular performance in septic
shock: a combined radionuclide and hemodynamic study. J
Am Coll Cardiol 4: 945–951.
Lambermont B, Gérard P, Kolh P, Detry O, Marcelle R, D’Orio
V (1998): Time domain method to identify simultaneously
parameters of the windkessel model applied to the pul-
monary circulation. Arch Physiol Biochem 106: 245–252.
Lambermont B, Kolh P, Detry O, Gérard P, Marcelle R, D’Orio
V (1999): Analysis of endotoxin effects on the intact pul-
monary circulation. Cardiovasc Res 41: 275–281.
Leeman M, Lejeune P, Hallemans R, Melot C, Naeije R (1988):
Effects of increased pulmonary vascular tone on gas-
exchange in canine oleic-acid pulmonary-edema. J Appl
Physiol 65: 662–668.
Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR,
Roberts LJ (1988): Clinical implications of prostaglandin
APB02_027
Effects of U-46619 Before and After BM-573 7
and thromboxane A2 formation (1). N Engl J Med 319:
689–698.
Ogletree ML, Brigham KL (1982): Effects of cyclooxygenase
inhibitors on pulmonary vascular responses to endotoxin 
in unanesthetized sheep. Prostaglandins Leukot Med 8:
489–502.
Rolin S, Dogne JM, Michaux C, Delarge J, Masereel B (2001):
Activity of a novel dual thromboxane A(2)receptor 
antagonist and thromboxane synthase inhibitor (BM-573)
on platelet function and isolated smooth muscles.
Prostaglandins Leukot Essent Fatty Acids 65: 67–72.
Schuster DP, Kozlowski JK, Brimioulle S (2001): Effects of
thromboxane receptor blockade on pulmonary capillary
hypertension in acute lung injury. Am J Respir Crit Care
Med 163: A820.
Sjoberg T, Steen S (1989): The strong contractile effect of the
thromboxane receptor agonist U-46619 in isolated human
pulmonary arteries and its competitive antagonism by BM-
13.505. Acta Physiol Scand 136: 161–165.
Smulders YM (2000): Pathophysiology and treatment of haemo-
dynamic instability in acute pulmonary embolism: the
pivotal role of pulmonary vasoconstriction. Cardiovasc Res
48: 23–33.
Vandeplassche G, Hemans C, Van de Water A, Xhonneux R,
Wouters L, Van Ammel K, de Clerck F (1991): Differential
effects of thromboxane A2 synthase inhibition, singly or
combined with thromboxane A2/prostaglandin endoperox-
ide receptor antagonism, on occlusive thrombosis elicited
by endothelial cell injury or by deep vascular damage in
canine coronary arteries. Circ Res 69: 313–324.
Vandeplassche G, Hermans C, Somers Y, Van de Werf F, de
Clerck F (1993): Combined thromboxane A2 synthase inhi-
bition and prostaglandin endoperoxide receptor antagonism
limits myocardial infarct size after mechanical coronary
occlusion and reperfusion at doses enhancing coronary
thrombolysis by streptokinase. J Am Coll Cardiol 21:
1269–1279.
Wise WC, Cook JA, Halushka PV (1981): Implications for
thromboxane A2 in the pathogenesis of endotoxic shock.
Adv Shock Res 6: 83–91.
APB02_027 
